Molecular pharmaceutics
A CD36-Targeting Thermosensitive Berberine Nanogel Blocks Tumor Lipid Hijacking and Potentiates Anti-PD-L1 Immunotherapy in Triple-Negative Breast Cancer.
Wanyu Jin, Shujun Xu, Hongyan Zhang, Yujie Li, Mengna Shi, Ninghui Ma, Xin Zhang, Lujia Zhu, Yang Xiong
Published: 202610.1021/acs.molpharmaceut.5c01378
Abstract
The limited efficacy of programmed death-ligand-1 (PD-L1) monoclonal antibodies (aPD-L1) in triple-negative breast cancer (TNBC) is largely attributable to the immunosuppressive tumor microenvironment (TME). Notably, the abundance of cancer-associate…
Preview only. Read the full abstract at the source